Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Healthia Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$1.80 |
52 Week High | AU$1.80 |
52 Week Low | AU$0.85 |
Beta | 1.08 |
1 Month Change | 1.13% |
3 Month Change | 3.16% |
1 Year Change | 63.18% |
3 Year Change | n/a |
5 Year Change | 57.46% |
Change since IPO | 41.90% |
Recent News & Updates
Recent updates
Shareholder Returns
HLA | AU Healthcare | AU Market | |
---|---|---|---|
7D | 0.1% | 2.6% | 0.9% |
1Y | 63.2% | -20.9% | 5.7% |
Return vs Industry: HLA exceeded the Australian Healthcare industry which returned -11% over the past year.
Return vs Market: HLA exceeded the Australian Market which returned -0.5% over the past year.
Price Volatility
HLA volatility | |
---|---|
HLA Average Weekly Movement | 0.6% |
Healthcare Industry Average Movement | 6.8% |
Market Average Movement | 8.9% |
10% most volatile stocks in AU Market | 17.5% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: HLA's share price has been volatile over the past 3 months.
Volatility Over Time: HLA's weekly volatility has decreased from 14% to 1% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | n/a | Wes Coote | www.healthia.com.au |
Healthia Limited provides health services in Australia. It operates through three segments: Feet & Ankles; Bodies & Minds; and Eyes & Ears. The company operates podiatry and retail footwear; physiotherapy, hand therapy, occupational therapy, exercise physiology, and speech pathology clinics; and optometry and audiology stores, as well as manufactures and sells orthotic devices.
Healthia Limited Fundamentals Summary
HLA fundamental statistics | |
---|---|
Market cap | AU$252.06m |
Earnings (TTM) | AU$5.47m |
Revenue (TTM) | AU$252.56m |
46.1x
P/E Ratio1.0x
P/S RatioIs HLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HLA income statement (TTM) | |
---|---|
Revenue | AU$252.56m |
Cost of Revenue | AU$175.80m |
Gross Profit | AU$76.75m |
Other Expenses | AU$71.29m |
Earnings | AU$5.47m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.039 |
Gross Margin | 30.39% |
Net Profit Margin | 2.16% |
Debt/Equity Ratio | 50.7% |
How did HLA perform over the long term?
See historical performance and comparison